Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latiglutenase in T1D Patients with Celiac Disease
NCT04839575Phase 2Terminated
- Sponsor
- Entero Therapeutics, Inc.
- Start
- Apr 2021
- Primary completion
- Dec 2022
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of latiglutenase in celiac disease, sponsored by Entero Therapeutics, Inc.. Started Apr 2021; status: terminated.
02
Drugs
latiglutenase
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT04839575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04839575.